Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients

American Journal of Transplantation

Volumn 7, Issue 5, 2007, Pages 1193-1200

  Evenepoel, P ^a   Naesens, M ^a   Claes, K ^a   Kuypers, D ^a   Vanrenterghem, Y ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

FGF 23; Phosphatonin; Vitamin D

Indexed keywords

BASILIXIMAB; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CYCLOSPORIN; FIBROBLAST GROWTH FACTOR 23; MALONONITRILAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHATE; TACROLIMUS; THYMOCYTE ANTIBODY; VITAMIN D;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MINERAL METABOLISM; PARATHYROID FUNCTION; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; PROTEIN INTERACTION; RECIPIENT; URINARY EXCRETION;

ADULT; BIOLOGICAL MARKERS; CALCITRIOL; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOPHOSPHATEMIA; KIDNEY TRANSPLANTATION; MIDDLE AGED; MINERALS; PARATHYROID HORMONE; PHOSPHATES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; VITAMIN D;

EID: 34247382124     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01753.x     Document Type: Article

References (41)

1. Ghanekar H, Welch BJ, Moe OW, Sakhaee K. Post-renal transplantation hypophosphatemia: A review and novel insights. Curr Opin Nephrol Hypertens 2006 15 : 97 104.
2. Green J, Debby H, Lederer E, Levi M, Zajicek HK, Bick T. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Int 2001 60 : 1182 1196.
3. Bacic D, Lehir M, Biber J, Kaissling B, Murer H, Wagner CA. The renal Na+/phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone. Kidney Int 2006 69 : 495 503.
4. Schiavi SC, Moe OW. Phosphatonins: A new class of phosphate-regulating proteins. Curr Opin Nephrol Hypertens 2002 11 : 423 430.
5. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000 26 : 345 348.
6. Saito H, Kusano K, Kinosaki M et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 2003 278 : 2206 2211.
7. Burnett SA, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 2006 21 : 1187 1196.
8. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005 16 : 2205 2215.
9. Shigematsu T, Kazama JJ, Yamashita T et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004 44 : 250 256.
10. Nakanishi S, Kazama JJ, Nii-Kono T et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005 67 : 1171 1178.
11. Kazama JJ, Sato F, Omori K et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005 67 : 1120 1125.
12. Bhan I, Shah A, Holmes J et al. Post-transplant hypophosphatemia: Tertiary 'hyper-phosphatoninism'?. Kidney Int 2006 70 : 1486 1494.
13. Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002 87 : 4957 4960.
14. Bouillon R, De Moor P, Baggiolini EG, Uskokovic MR. A radioimmunoassay for 1,25-dihydroxycholecalciferol. Clin Chem 1980 26 : 562 567.
15. Bouillon R, Van Herck E, Jans I, Tan BK, Van Baelen H, De Moor P. Two direct (nonchromatographic) assays for 25-hydroxyvitamin D. Clin Chem 1984 30 : 1731 1736.
16. Bouillon R, Coopmans W, Degroote DE, Radoux D, Eliard PH. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. Clin Chem 1990 36 : 271 276.
17. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 42 (Suppl 3 S1 S201.
18. Souberbielle JC, Boutten A, Carlier MC et al. Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 2006 70 : 345 350.
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 130 : 461 470.
20. Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet 1975 2 : 309 310.
21. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: Regulation by phosphate? Bone 2004 35 : 1192 1199.
22. Kolek OI, Hines ER, Jones MD et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: The final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005 289 : G1036 G1042.
23. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006 17 : 1305 1315.
24. Krocker D, Perka C, Tuischer J et al. Effects of tacrolimus, cyclosporin A and sirolimus on MG63 cells. Transpl Int 2006 19 : 563 569.
25. Falkiewicz K, Kaminska D, Nahaczewska W et al. Renal function and tubular phosphate handling in long-term cyclosporine- and tacrolimus-based immunosuppression in kidney transplantation. Transplant Proc 2006 38 : 119 122.
26. Levi M. Post-transplant hypophosphatemia. Kidney Int 2001 59 : 2377 2387.
27. Wu MS, Hung CC, Chang CT. Renal calcium handling after rapamycin conversion in chronic allograft dysfunction. Transpl Int 2006 19 : 140 145.
28. Schwarz C, Bohmig GA, Steininger R, Mayer G, Oberbauer R. Impaired phosphate handling of renal allografts is aggravated under rapamycin-based immunosuppression. Nephrol Dial Transplant 2001 16 : 378 382.
29. Kobayashi K, Imanishi Y, Miyauchi A et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol 2006 154 : 93 99.
30. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001 98 : 6500 6505.
31. Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Nephrol Dial Transplant 2004 19 : 1281 1287.
32. Pande S, Ritter CS, Rothstein M et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 2006 104 : p23 p32.
33. Ghanekar H, Moe OW, Sakhaee K. Post renal transplantation hypophosphatemia: Natural history and pathogenesis [abstract]. J Am Soc Nephrol 2005 16 : 758A.
34. Felsenfeld AJ, Gutman RA, Drezner M, Llach F. Hypophosphatemia in long-term renal transplant recipients: Effects on bone histology and 1,25-dihydroxycholecalciferol. Miner Electrolyte Metab 1986 12 : 333 341.
35. Bacic D, Wagner CA, Hernando N, Kaissling B, Biber J, Murer H. Novel aspects in regulated expression of the renal type IIa Na/Pi-cotransporter. Kidney Int Suppl 2004 91 : S5 S12.
36. Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation 2005 79 : 108 115.
37. Steiner RW, Ziegler M, Halasz NA, Catherwood BD, Manolagas S, Deftos LJ. Effect of daily oral vitamin D and calcium therapy, hypophosphatemia, and endogenous 1-25 dihydroxycholecalciferol on parathyroid hormone and phosphate wasting in renal transplant recipients. Transplantation 1993 56 : 843 846.
38. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW. Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 2004 101 : 7711 7715.
39. Bouillon RA, Auwerx JH, Lissens WD, Pelemans WK. Vitamin D status in the elderly: Seasonal substrate deficiency causes 1,25-dihydroxycholecalciferol deficiency. Am J Clin Nutr 1987 45 : 755 763.
40. Imel EA, Peacock M, Pitukcheewanont P et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006 91 : 2055 2061.
41. Ito N, Fukumoto S, Takeuchi Y et al. Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 2005 23 : 435 440.